Contineum Therapeutics, Inc. (CTNM)
(Real Time Quote from BATS)
$16.60 USD
+0.03 (0.18%)
Updated Oct 17, 2024 01:01 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Contineum Therapeutics, Inc. (CTNM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$28.67 | $32.00 | $25.00 | 73.02% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Contineum Therapeutics, Inc. comes to $28.67. The forecasts range from a low of $25.00 to a high of $32.00. The average price target represents an increase of 73.02% from the last closing price of $16.57.
Analyst Price Targets (3 )
Broker Rating
Contineum Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/30/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $28.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -0.41 |
CTNM FAQs
Contineum Therapeutics, Inc. (CTNM) currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Contineum Therapeutics, Inc. (CTNM) is $28.67. The current on short-term price targets is based on 2 reports.
The forecasts for Contineum Therapeutics, Inc. (CTNM) range from a low of $25 to a high of $32. The average price target represents a increase of $73.02 from the last closing price of $16.57.
The current UPSIDE for Contineum Therapeutics, Inc. (CTNM) is 73.02%
Based on short-term price targets offered by three analysts, the average price target for Contineum Therapeutics, Inc. comes to $28.67. The forecasts range from a low of $25.00 to a high of $32.00. The average price target represents an increase of 73.02% from the last closing price of $16.57.